Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.31 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7795202 | 0.88 | MEN1 (0.37) | KMT2AMEN1PDE4APDE3APTPN1 | |
| SCHEMBL7795590 | 0.79 | PPARG (0.34) | KMT2AMEN1ALOX5ALDH1A1 | |
| SCHEMBL9816262 | 0.75 | PTGS1 (0.54) | KMT2AMEN1ALOX5NR1I2LMNA | |
| SCHEMBL5858834 | 0.74 | PPARG (0.40) | ALOX5NR1I2LMNA | |
| SCHEMBL7330589 | 0.72 | MEN1 (0.58) | KMT2AMEN1PDE4APDE3APTPN1 | |
| SCHEMBL7795663 | 0.70 | PLG (0.39) | PTPN1GSTO1PSEN1ALOX5 | |
| SCHEMBL5860037 | 0.69 | PPARG (0.45) | NR1I2ALDH1A1 | |
| SCHEMBL24157975 | 0.68 | KMT2A (0.48) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL5859969 | 0.67 | L3MBTL1 (0.44) | KMT2AALOX5NR1I2L3MBTL1 | |
| SCHEMBL7795257 | 0.67 | PPARG (0.34) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| US-6225480-B1 | FOR SYNTHESIS OF ORGANIC COMPOUNDS CONTAINING--NH--GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | H1-0, H1-2, ASH2L | KMT2A 173/4885MEN1 1879/4885PDE4A 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.